Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination wi...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English |
Published |
07.01.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination with one or more additional therapeutic agents. |
---|---|
Bibliography: | Application Number: AU20190274203 |